GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Degree of Operating Leverage

IMMX (Immix Biopharma) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Immix Biopharma does not have enough data to calculate Degree of Operating Leverage.


Immix Biopharma Degree of Operating Leverage Historical Data

The historical data trend for Immix Biopharma's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma Degree of Operating Leverage Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial - - - - -

Immix Biopharma Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immix Biopharma's Degree of Operating Leverage

For the Biotechnology subindustry, Immix Biopharma's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immix Biopharma's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's Degree of Operating Leverage falls into.


;
;

Immix Biopharma Degree of Operating Leverage Calculation

Immix Biopharma's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -21.767 (Mar. 2025) / -19.211 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=0.133/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Immix Biopharma  (NAS:IMMX) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Immix Biopharma Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Immix Biopharma Business Description

Traded in Other Exchanges
N/A
Address
11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Executives
Jason Hsu director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Ilya M Rachman director, officer: CEO and Chairman 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris director, officer: Chief Financial Officer 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Helen C. Adams director 15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan director 1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky director, 10 percent owner C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Sean Senn 10 percent owner 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin officer: Scientific Co-Founder 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross officer: CMO & Head of Clinical Dev. 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064

Immix Biopharma Headlines

From GuruFocus